WO2025120583 - CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/120583
Publication Date
12.06.2025
International Application No.
PCT/IB2024/062299
International Filing Date
06.12.2024
Title **
[English]
CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
[French]
ANTICORPS CD33, ANTICORPS MULTISPÉCIFIQUES CD33/Vδ2 ET LEURS UTILISATIONS
Applicants **
JANSSEN BIOTECH, INC.
Inventors
ELASHKAR, Sara Mohamed A
KALLAL, Lorena A
JACOBS, Steven A.
PHILIPPAR, Ulrike
DOONAN, Patrick John
PARREN, Paul Willem Henri Ida
MERAT, Sabrina Julia Louisa
ROOVERS, Robertus Cornelis
VAN DER VLIET, Johannes Jelle
VAN HELDEN, Paula Maria Wilhelmina
Priority Data
63/608,030
08.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4619 | |
| EPO | Filing, Examination, Granting | 58504 | |
| Japan | Filing, Examination, Granting | 3943 | |
| South Korea | Filing, Examination, Granting | 5699 | |
| USA | Filing, Examination, Granting | 21190 |
Total:
93,955
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
CD33 antibodies, and antigen-binding fragments thereof, and CD33/Vδ2 multispecific antibodies, or antigen-binding fragments thereof, are described. Also described are polynucleotides encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as hematological cancers.[French]
L'invention concerne des anticorps CD33, et des fragments de liaison à l'antigène de ceux-ci, et des anticorps multispécifiques CD33/Vδ2, ou des fragments de liaison à l'antigène de ceux-ci. L'invention concerne également des polynucléotides codant pour les anticorps, des compositions comprenant les anticorps, des procédés de production des anticorps, et des procédés d'utilisation des anticorps pour traiter ou prévenir des maladies, telles que des cancers hématologiques.